Provectus Biopharmaceuticals Inc (PVCT)

[Fruno]

This is very good news. In retrospect, it shouldn't be a surprise. This is from the abstract: "In murine models of breast cancer and melanoma, we have shown that IL injection of PV-10 (10% RB in saline solution) leads to ablation of injected tumors and regression of non-injected bystander tumors. In these models, increased anti-tumor T cell responses were measured, supporting the induction of systemic anti-tumor immunity after tumor ablation with PV-10. In our ongoing phase I clinical trial exploring melanoma regression in patients...".

Moffitt worked with breast cancer cells in the pre-clinical part of the study, where the results where the same as with melanoma cells. But they only studied melanoma in Phase 1 (human) portion, and that is what most of the discussion was about. Now we know why they did the preliminary breast cancer work. (I wonder why liver wasn't included, too.)

Great to have people out there connecting the dots.

There are no papers or presentations of the Phase 1 breast cancer data listed on PVCT's website. This is the only discussion about it that I can find, also from the website: "In October 2008, the Phase 1 study was completed successfully. 12 subjects received IL PV-10 treatment. Treatment was well tolerated in all subjects, with no evidence of systemic or serious local side effects. Several subjects exhibited evidence of efficacy, including tumor ablation or shrinkage."

IIRC, they injected tumors, then studied them after they were surgically removed. In other words, the women continued on with standard treatment, so there was no long-term follow-up.